Skip to content

ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier

ScaiDigest Volume 3

ScaiDigest Volume 3 

ScaiDigest Volume 3

We’re thrilled to present the latest edition of ScaiDigest, your bi-weekly rendez-vous with cutting-edge science! 

In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-cell and multi-omics technologies in immuno-oncology. 

Delve into groundbreaking research that underscores the potential of multi-omics approaches. The recent articles by Tretter et al. in Nature Communications and Wong et al. in Frontiers in Immunology are illuminating the path toward new horizons in cancer research.

Witness the power of comprehensive multi-omics strategies, from RNA-based data integration to high-dimensional genomics and immune analysis. These studies unlock new dimensions of tumour immunogenicity and personalized treatment strategies.

Join Diana as she navigates through the intricate world of multi-omics and immuno-oncology. Read the full post by clicking below and stay tuned for more captivating scientific insights from the forefront of discovery!

“As a firm believer in our potential to solve biological problems, I identify single-cell and multi-omics technologies as a prime contender in the race to provide a whole new dimension of data that will answer open and complex biological questions. My confidence in the possibilities of these technologies  has been recently justified as two articles adopting multi-omic approaches to address unmet needs in immuno-oncology were published in the last several weeks.

The article by Tretter et al. in Nature Communications underscores the importance of a multi-omics approach for the discovery and assessment of neoantigens in various cancer types. It demonstrates the value of integrating RNA-based data and non-canonical HLA-binding peptides in immuno-oncology research. These trends highlight the ongoing advancements in single-cell multi-omics technologies for enhancing our understanding of tumor immunogenicity and the development of personalized cancer treatments.

Specifically, the study adopts a comprehensive multi-omics approach, including DNA and RNA sequencing, as well as MS-based immunopeptidomics of tumor specimens. This indicates a growing trend in utilizing multiple omics techniques to obtain a more holistic understanding of the molecular and immunological characteristics of tumors.

The primary focus of the study is on the discovery of neoantigens, which are unique antigens derived from tumor-specific mutations. The use of computational methods in combination with multi-omics data enables the identification of a large number of tumor-specific and tumor-associated antigens, enhancing our understanding of cancer immunogenicity.

Interestingly, the majority of neoantigen candidates are found to originate from variants identified in the RNA data set. This underscores the significance of RNA as a source of cancer antigens, challenging the traditional focus on DNA variants alone. This trend emphasizes the importance of integrating RNA-based data in immuno-oncology research.

Another study by Wong et al. published in Frontiers in Immunology emphasizes the integration of multi-omics technologies in a phase 1 clinical trial for relapsed/refractory multiple myeloma. The study showcases a bold approach to identifying predictive biomarkers through high-dimensional genomics and immune data analysis, contributing to the ongoing advancement of personalized treatment strategies in immuno-oncology.

Phase 1b Clinical Trial Design: The study focuses on a phase 1b clinical trial (NCT02431208) to evaluate the safety and efficacy of the anti-programmed death-ligand 1 monoclonal antibody atezolizumab (Atezo). A novel unsupervised integrative multi-omic analysis is conducted using RNA sequencing, mass cytometry immunophenotyping, and proteomic profiling of baseline and on-treatment bone marrow samples. This advanced analytical approach underscores the integration of various omics data sources to gain a comprehensive understanding of the disease and treatment effects.

The high-dimensional multi-omic profiling and integrative Similarity Network Fusion analysis reveal novel correlations between cellular and molecular features of the tumor and immune microenvironment. The integrative analysis’s findings have implications for patient selection and outcome assessment in future immunotherapy studies. 

These studies underscore the importance of incorporating advanced multi-omics strategies in research and clinical trial design to guide the development of novel therapies and treatment decisions.”


Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification.

Tretter C, de Andrade Krätzig N, Pecoraro M, Lange S, Seifert P, von Frankenberg C, Untch J, Zuleger G, Wilhelm M, Zolg DP, Dreyer FS, Bräunlein E, Engleitner T, Uhrig S, Boxberg M, Steiger K, Slotta-Huspenina J, Ochsenreither S, von Bubnoff N, Bauer S, Boerries M, Jost PJ, Schenck K, Dresing I, Bassermann F, Friess H, Reim D, Grützmann K, Pfütze K, Klink B, Schröck E, Haller B, Kuster B, Mann M, Weichert W, Fröhling S, Rad R, Hiltensperger M, Krackhardt AM.

Nat Commun. 2023 


Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM

Sandy Wong, Habib Hamidi, Luciano J. Costa, Selma Bekri, Natalia Neparidze, Ravi Vij, Tina G. Nielsen, Aparna Raval, Rajan Sareen, Elisabeth Wassner-Fritsch, Hearn J. Cho

Front Immunol. 2023

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Recent News

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Recent News

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Recent News

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Recent News

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News

01 /04

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

02 /04

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

03 /04

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

04 /04

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News